目的 探討香菇多糖注射液聯(lián)合伊立替康治療晚期結(jié)直腸癌的臨床療效。方法 選取2015年9月-2016年9月在南方醫(yī)科大學(xué)南方醫(yī)院接受治療的晚期結(jié)直腸癌患者74例，隨機(jī)分為對照組（37例）和治療組（37例）。對照組靜脈滴注鹽酸伊立替康注射液，180 mg/m²加入250 mL生理鹽水中，1次/3周。治療組在對照組的基礎(chǔ)上靜脈滴注香菇多糖注射液，2 mL加入5%葡萄糖溶液250 mL中，1次/d。兩組患者均連續(xù)治療6周。治療后，比較兩組患者臨床效果、生存質(zhì)量改善情況和血清學(xué)指標(biāo)。結(jié)果 治療后，對照組與治療組的客觀緩解率（ORR）分別為48.65%、70.27%，臨床獲益率（CBR）分別為70.27%、91.89%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，對照組生存質(zhì)量總改善率為72.97%，顯著低于治療組的94.59%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者基質(zhì)金屬蛋白酶-2（MMP-2）水平均下降，而白細(xì)胞介素-2（IL-2）和干擾素-γ（IFN-γ）水平均升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組患者的上述觀察指標(biāo)改善情況顯著優(yōu)于對照組患者，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 香菇多糖注射液聯(lián)合伊立替康治療晚期結(jié)直腸癌具有較好的臨床療效，可明顯提高機(jī)體免疫能力和改善生活質(zhì)量，具有一定的臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of Xianggu Duotang Injection combined with irinotecan in treatment of advanced colorectal cancer. Methods Patients (74 cases) with advanced colorectal cancer in Nanfang Hospital of Southern Medical University from September 2015 to September 2016 were randomly divided into control (37 cases) and treatment (37 cases) groups. Patients in the control group were iv administered with Irinotecan Hydrochloride Injection, 180 mg/m² diluted into 250 mL normal saline, once every 3 weeks. Patients in the treatment group were iv administered with Xianggu Duotang Injection on the basis of the control group, 2 mL added into 5% glucose solution (250 mL), once daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy, improvement of quality of life, and serological indexes in two groups were compared. Results After treatment, ORR in the control and treatment groups were 48.65% and 70.27% respectively, and CBR in two groups were 70.27% and 91.89%, there was difference between two groups (P < 0.05). After treatment, the improvement rate of quality of life in the control group was 72.97%, which was significantly lower than 94.59% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, MMP-2 in two groups was significantly decreased, but IL-2 and IFN-γ were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observation indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xianggu Duotang Injection combined with irinotecan has good clinical efficacy in treatment of advanced colorectal cancer, can significantly improve the immune capacity and quality of life, which has a certain clinical application value.